Neurizon Therapeutics Limited

NUZ

AU0000357261

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 10:40:28 06/02/2026 am IST			5-day change	1st Jan Change
0.0930 ^AUD	-7.00%		+10.71%	+9.41%

20/01	Neurizon Therapeutics Obtains Global Trademark Protection in Major Markets	MT
20/01	Neurizon Therapeutics secures registered trademark protection for Neurizon® across all priority global markets	RE

Neurizon Completes Manufacturing Three Registration Batches of Drug Candidate to Treat Neurodegenerative Disease; Shares Fall 5%

Published on 12/04/2025 at 07:13 am IST

MT Newswires

Latest news about Neurizon Therapeutics Limited

20/01	Neurizon Therapeutics Obtains Global Trademark Protection in Major Markets	MT
20/01	Neurizon Therapeutics secures registered trademark protection for Neurizon® across all priority global markets	RE
02/01	FDA Denies Neurizon Therapeutics' Request for Fast Track Designation for ALS Treatment Candidate	MT
02/01	Neurizon Therapeutics says US FDA denies Fast Track designation for NUZ-001	RE
23/12	Neurizon Therapeutics says firm commitments to raise A$7.1 million via placement	RE
23/12	Neurizon Therapeutics to Raise Over AU$7 Million via Share Placement; Shares Hit 52-Week Low	MT
19/12	Neurizon Therapeutics seeks trading halt	RE
11/12	Neurizon Says US FDA Clears Use of Drug Candidate in ALS Clinical Trial	MT
04/12	Neurizon Completes Manufacturing Three Registration Batches of Drug Candidate to Treat Neurodegenerative Disease; Shares Fall 5%	MT
26/11	Neurizon Therapeutics Limited Announces the Appointment of Justine Conway as Board Observer	CI
21/25/21	Neurizon Therapeutics Secures Australian Patent Covering NUZ-001 Drug Candidate for Neurodegenerative Disease Treatment	MT
06/25/06	Neurizon Therapeutics Limited Announces U.S. Food and Drug Administration Lifts Clinical Hold on Nuz-001	CI
06/25/06	FDA lifts clinical hold on Nuz-001	RE
06/25/06	Neurizon Therapeutics says US FDA lifts clinical hold on NUZ-001	RE
06/25/06	Neurizon Therapeutics Says US FDA Lifts Clinical Hold on Amyotrophic Lateral Sclerosis Drug Candidate	MT
18/25/18	Neurizon Therapeutics Secures AU$5 Million Through Share Placement	MT
18/25/18	Neurizon Therapeutics raises A$5 million at A$0.12 per share	RE
16/25/16	Neurizon Therapeutics seeks trading halt	RE
26/25/26	Neurizon Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2025	CI
26/25/26	Neurizon Therapeutics posts loss for year attributable a$16.6 million	RE
20/25/20	Neurizon Therapeutics Says ALS Drug Candidate Study Confirms Long-Term Treatment at Recommended Dose is Safe, Well-Tolerated	MT
15/25/15	Neurizon Says US FDA Delays Decision on ALS Drug Application Clinical Hold; Shares Fall 6%	MT
12/25/12	Neurizon Starts Manufacturing First Registration Batch of Drug Candidate to Treat Neurodegenerative Disease	MT
30/25/30	Neurizon Therapeutics Secures AU$1.5 Million Loan Against Fiscal Year 2025 R&D Tax Rebate	MT
25/25/25	Neurizon Therapeutics Submit Formal Response to US FDA for Investigational New Drug Application; Shares Up 19%	MT

Chart Neurizon Therapeutics Limited

Duration

Period

NUZ: Dynamic Chart

Neurizon Therapeutics Ltd, formerly PharmAust Limited, is an Australia-based clinical-stage biotechnology company. The Company is engaged in advancing treatments for neurodegenerative diseases. The Company is focused on developing its lead drug candidate, NUZ-001, for the treatment of Amyotrophic Lateral Sclerosis (ALS), which is the common form of motor neuron disease. ALS is a devastating neurodegenerative condition that primarily affects nerve cells that control voluntary muscles.

Employees

Sector

Pharmaceuticals

Calendar

26/02 - Q2 2026 Earnings Release (Projected)

More about the company